Results 91 to 100 of about 13,526 (188)

Contemporary Concise Review 2025: Interstitial Lung Disease

Respirology, Volume 31, Issue 10, Page 974-982, October 2026.
ABSTRACT Multidisciplinary discussion remains the cornerstone of ILD diagnosis and management, with recent advances further strengthening the integration of clinical, radiological, pathological, and molecular information. Updated ILD nomenclature and classification better align disease terminology with underlying morphology and pathobiology.
Tonia Magrì, Luca Richeldi
wiley   +1 more source

Nintedanib enhances tumor cell radiosensitivity by promoting ferroptosis and modulating the ATF4/SLC7A11/GSH axis

Cancer Biology & Medicine
Objective: Tumor cell radio-resistance and radiation-induced fibrosis of normal tissues hinder the efficacy of radiotherapy. Nintedanib, a promising therapeutic agent for radiation-induced pulmonary fibrosis and solid tumors, has yet to be investigated ...
Chunya Li, Aifeina Aili, Qingqing Yu, Mu Yang, Qiyuan Feng, Duo Xu, Bo Liu, Jingyao Tu, Xianglin Yuan   +8 more
doaj   +1 more source

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study

, 2018
Mitsuhiro Abe,1 Kenji Tsushima,1,2 Masashi Sakayori,1 Kenichi Suzuki,1 Jun Ikari,1 Jiro Terada,1 Koichiro Tatsumi1 1Department of Respirology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba city, Chiba 260-8670, Japan; 2Department of ...
Terada J, Tsushima K, Abe M, Ikari J, Suzuki K, Tatsumi K, Sakayori M   +6 more
core  

Response evaluation of neoadjuvant therapy in MIBC: clinical trial‐derived evidence to guide practice

BJU International, Volume 138, Issue 4, Page 558-564, October 2026.
Objectives To review how response to neoadjuvant therapy (NAT) is assessed in clinical trials of muscle‐invasive bladder cancer (MIBC), and to determine whether trial‐derived evidence can inform response evaluation in contemporary practice. Subjects/Patients and Methods We searched PubMed, Embase and ClinicalTrials.gov through August 2025 for ...
Roberto Contieri, Bas W.G. van Rhijn, Richard Cathomas, Anja Lorch, Daniela Oprea‐Lager, Paramananthan Mariappan, Francesco Sanguedolce, Antoine G. van der Heijden, Laura S. Mertens, In collaboration with the EAU Imaging Section   +9 more
wiley   +1 more source

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

, 2019
Preclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression of lung fibrosis.
Flaherty, Kevin R, Goeldner, Rainer Georg, Rosenstock, B., Kolb, Martin, Brown, K. K., Stowasser, Susanne, Park, Jong Sun, Walsh, S. L. F., Coeck, C., Inoue, Yoshikazu, Quaresma, Manuel, Clerisme-Beaty, E., Brown, Kevin K, Brown, Keith, Schlenker-Herceg, R., Coeck, Carl, Wells, Athol U, Walsh, Simon L F, Haeufel, T., Goeldner, R-G, Rosenstock, Bernd, Cottin, V, Quaresma, M., Devaraj, A., Richeldi, L., Goeldner, Rainer-Georg, Inoue, Y., Wells, A. U., Dahlqvist, Caroline, Haeufel, Thomas, Cottin, Vincent, Flaherty, K. R., Tetzlaff, K., Tetzlaff, Kay, Stowasser, S., INSTAGE Investigator, Bondue Benjamin, Clerisme-Beaty, Emmanuelle, Richeldi L., Bondue, Benjamin, Schlenker-Herceg, Rozsa, Devaraj, Anand, Richeldi, Luca, INBUILD Trial Investigators, Kolb, M.   +43 more
core   +1 more source

Systemic pirfenidone treatment fails to mitigate fibrosis and compromises functional recovery in a porcine model of volumetric muscle loss

Experimental Physiology, Volume 111, Issue 10, Page 4286-4295, 1 October 2026.
Abstract Repurposing clinically approved antifibrotic agents presents a potential near‐term therapeutic strategy to mitigate the extensive fibrotic scarring that follows severe volumetric muscle loss (VML) injury and inhibits functional recovery. We hypothesized that daily oral administration of pirfenidone, an FDA‐approved antifibrotic, would mitigate
Jessica M. Motherwell, Ondine Eken, Claudia E. Hernandez, Christopher L. Dearth, Stephen M. Goldman   +4 more
wiley   +1 more source

Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease

Arthritis Research & Therapy
We used data from the SENSCIS and SENSCIS-ON trials to assess decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who received long-term treatment with nintedanib and the effect of ...
Oliver Distler, Madelon C Vonk, Arata Azuma, Maureen D. Mayes, Dinesh Khanna, Kristin B. Highland, Gerrit Toenges, Margarida Alves, Yannick Allanore   +8 more
doaj   +1 more source

Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis

, 2018
BACKGROUND: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the diffusion ...
Schinzel, Birgit, Martinez, INSTAGE Trial Investigators, Benjamin Bondue, Kolb, Martin, Stowasser, Susanne, Martinez, Fernando, Raghu, Ganesh, Martinez, Fernando J., Investigators, INSTAGE, Quaresma, Manuel, Bourdin, Arnaud, Maria Pia Foschino Barbaro, Fernando J, Wells, Athol U, Wells, Athol U., Richeldi L., Bondue, Benjamin, INSTAGE Investigator, Behr, Jürgen, Richeldi, Luca   +19 more
core   +1 more source

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Response to letter]

, 2019
Mitsuhiro Abe,1 Kenji Tsushima,1,2 Koichiro Tatsumi11Department of Respirology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba city, Chiba 260-8670, Japan; 2Department of Pulmonary Medicine, International University of Health and Welfare ...
Tsushima K, Abe M, Tatsumi K
core  

Proteomic study on nintedanib in gastric cancer cells [PDF]

Background Gastric cancer is a very common gastrointestinal tumor with a high mortality rate. Nintedanib has been shown to significantly reduce tumor cell proliferation and increase apoptosis in gastric cancer cells in vitro. However, its systemic action
Xiao jun Yang, Xiaohua Dong, Miao Yu, Hui Cai, Liuli Wang, Da Wang   +5 more
core   +1 more source